Rapid determination of some psychotropic drugs in complex matrices by tandem dispersive liquid-liquid microextraction followed by high performance liquid chromatography.

Simple and rapid determinations of some psychotropic drugs in some pharmaceutical wastewater and human plasma samples were successfully accomplished via the tandem dispersive liquid-liquid microextraction combined with high performance liquid chromatography-ultraviolet detection (TDLLME-HPLC-UV). TDLLME of the three psychotropic drugs clozapine, chlorpromazine, and thioridazine was easily performed through two consecutive dispersive liquid-liquid microextractions. By performing this convenient method, proper sample preconcentrations and clean-ups were achieved in just about 7min. In order to achieve the best extraction efficiency, the effective parameters involved were optimized. The optimal experimental conditions consisted of 100µL of CCl4 (as the extraction organic solvent), and the pH values of 13 and 2 for the donor and acceptor phases, respectively. Under these optimum experimental conditions, the proposed TDLLME-HPLC-UV technique provided a good linearity in the range of 5-3000ngmL-1 for the three psychotropic drugs with the correlation of determinations (R2s) higher than 0.996. The limits of quantification (LOQs) and limits of detection (LODs) obtained were 5.0ngmL-1 and 1.0-1.5ngmL-1, respectively. Also the proper enrichment factors (EFs) of 96, 99, and 88 for clozapine, chlorpromazine, and thioridazine, respectively, and good extraction repeatabilities (relative standard deviations below 9.3%, n=5) were obtained.

Bioconcentration of two basic pharmaceuticals, verapamil and clozapine, in fish.

The present study examined the bioconcentration of 2 basic pharmaceuticals: verapamil (a calcium channel blocker) and clozapine (an antipsychotic compound) in 2 fresh water fishes, fathead minnow and channel catfish. In 4 separate bioconcentration factor (BCF) experiments (2 chemicals × 1 exposure concentration × 2 fishes), fathead minnow and channel catfish were exposed to 190 µg/L and 419 µg/L of verapamil (500 µg/L nominal) or 28.5 µg/L and 40 µg/L of clozapine (50 µg/L nominal), respectively. Bioconcentration factor experiments with fathead consisted of 28 d uptake and 14 d depuration, whereas tests conducted on catfish involved a minimized test design, with 7 d each of uptake and depuration. Fish (n = 4-5) were sampled during exposure and depuration to collect different tissues: muscle, liver, gills, kidneys, heart (verapamil tests only), brain (clozapine tests only), and blood plasma (catfish tests only). Verapamil and clozapine concentrations in various tissues of fathead and catfish were analyzed using liquid chromatography-mass spectrometry. In general, higher accumulation rates of the test compounds were observed in tissues with higher perfusion rates. Accumulation was also high in tissues relevant to pharmacological targets in mammals (i.e. heart in verapamil test and brain in the clozapine test). Tissue-specific BCFs (wet wt basis) for verapamil and clozapine ranged from 0.7 to 75 and from 31 to 1226, respectively. Tissue-specific concentration data were used to examine tissue-blood partition coefficients.

[The determination of clozapine for the forensic chemical study of the cadaveric blood, urine, and liver using high performance liquid chromatography].

The method for the determination of clozapine during chemical studies of cadaveric blood, urine, and liver (kidneys) has been developed based on the use of high performance liquid chromatography. Clozapine losses were estimated at 40-60% with the fractional uncertainty below 10-11% and the detection limit of 0.001 mg%. An algorithm for the estimation of the quality of clozapine isolation and the results of analysis of individual samples is proposed.

Ionic liquid-based liquid phase microextraction with direct injection for capillary electrophoresis.

Liquid-liquid microextraction using the water immiscible ionic liquid, 1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, EMIM NtfO2, for the concentration and cleanup of basic compounds for analysis by CE has been investigated. Using an electrolyte comprising 1 mol/L alanine and 3 mol/L acetic acid, EMIM NtfO2 could be directly injected into the capillary after liquid phase extraction. Using the basic dye chryisoidine, sensitivity enhancements approaching 1000-fold were obtained by mixing 20 µL of EMIM NtfO2 with 1500 µL of aqueous sample, leaving only 5 µL of the undissolved ionic liquid which was used for injection into the CE. Lower more repeatable enhancement factors of 200-fold were obtained with slightly larger initial 25 µL volumes of EMIM NtfO2 due to the larger residual volume of ionic liquid which made handling easier. This could be extended to basic pharmaceuticals, and the extraction of clozapine and its two active metabolites, nor-clozapine and clozapine-N-oxide, was demonstrated from urine with enrichment factors greater than 100 obtained. Handling of potentially more dangerous samples, such as serum, through in-vial extraction of clozapine and its metabolites and direct injection of the ionic liquid layer was also demonstrated with enhancements in sensitivity of 80. Limits of detection from 3 to 11 µg/L and 6 to 55 µg/L were obtained from urine and serum, respectively, which are sufficiently low to be useful for the determination of these pharmaceuticals clinically for therapeutic drug monitoring and for forensic toxicology.

Separation of antipsychotic drugs (clozapine, loxapine) and their metabolites by capillary zone electrophoresis.

Two antipsychotic drugs (clozapine and loxapine) and six metabolites, N-demethylclozapine, clozapine N-oxide, N-demethylloxapine (amoxapine), 7-hydroxyloxapine, 8-hydroxyloxapine, 8-hydroxyamoxapine, were separated by capillary zone electrophoresis. Variation of pH and ionic strength of the acidic phosphate buffer (pH below 4) did not enable the separation of loxapine and one of its metabolites. Resolution of the single parent drugs and their metabolites was possible in background electrolytes (phosphate, pH 3.5, 60 mmol/l) containing either 0.2% (w/v) polyvinylpyrrolidone as replaceable pseudo-stationary phase, or 0.75 mmol/l beta-cyclodextrin added as complex-forming agent. Full separation of the mixture with baseline resolution of all analytes was obtained with a background electrolyte with heptakis-6-sulfato-beta-cyclodextrin added as negatively charged complexation agent with improved separation selectivity.

[The determination of clozapine in blood and urine by gas chromatography-mass spectrometry]. / Opredelenie klozapina v krovi i moche metodom gazovoi khromatografii--mass-spektrometrii.

A method for measuring closapine in the blood and urine by gas chromatography-mass spectrometry as a trifluoroacetic derivative is proposed. The threshold level for closapine detection is 25 ng/ml in the blood and 30 ng/ml in the urine. Calibration curves are linear in the range 0.025-5 mcg/ml for the blood and 0.03-50 mcg/ml for the urine. The method can be used in forensic chemical and clinical toxicological analysis.

Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma.

A rapid high-performance liquid chromatographic method for the simultaneous quantitation of plasma clozapine and its principal metabolite, norclozapine, was developed using a Spherisorb C8 5-micron reverse-phase column and an acetonitrile/potassium phosphate buffer/triethylamine mobile phase. Clozapine and norclozapine were extracted from plasma on solid-phase reusable microcolumns. Absolute recovery of clozapine, norclozapine, and the internal standard, flurazepam, was quantitative. The mean intraassay coefficient of variation was better than 6% for clozapine and norclozapine at therapeutic concentrations. Based on a plasma sample volume of 200 microliters, the limit of accurate quantitation of both clozapine and norclozapine was approximately 25 micrograms/L (coefficients of variation = 11.4% and 8.4%, respectively). The method has been used over the past 2 years for single-dose pharmacokinetic studies and for monitoring patients receiving clozapine therapy.